Trial reportAmerican journal of respiratory and critical care medicine2009
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.
Trial report in American journal of respiratory and critical care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pneumococcal Vaccine Response in COPD
A Randomized, Open-label, Parallel Design Study to Compare the Immunogenicity of Simultaneous Administration Versus Sequential Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2017Pooled it
- The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Deutsches Arzteblatt international · 2016Pooled it
- Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.Human vaccines & immunotherapeutics · 2018Trial
- Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.Journal of the International AIDS Society · 2016Trial
- Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.Arthritis research & therapy · 2015Trial
- Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- Trial
- Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?Vaccine · 2026Review
- Review
- Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS.Clinical immunology (Orlando, Fla.) · 2023Article
- Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.Vaccines · 2021Review
- Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.PloS one · 2020Article
- Phenotypic and molecular study of pneumococci causing respiratory tract infections. A 3-year prospective cohort.Saudi medical journal · 2017Article
- Pneumococcal vaccination and chronic respiratory diseases.International journal of chronic obstructive pulmonary disease · 2017Review
- A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2017Article
- Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.International journal of molecular sciences · 2016Review
- Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Clinical and vaccine immunology : CVI · 2016Review
- Pneumococcus with the "6E" cps Locus Produces Serotype 6B Capsular Polysaccharide.Journal of clinical microbiology · 2016Article
- Theory and strategy for Pneumococcal vaccines in the elderly.Human vaccines & immunotherapeutics · 2016Article
- A Decade of National Heart, Lung, and Blood Institute Programs Supporting COPD Research and Education .Chronic obstructive pulmonary diseases (Miami, Fla.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
Abstract
rationaleDebate exists about the immunogenicity and protective efficacy of antibodies produced by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in chronic obstructive pulmonary disease (COPD). The 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) induces a more robust immune response than PPSV23 in healthy elderly adults.
objectivesWe hypothesized that serotype-specific IgG antibody concentration and functional antibody activity would be superior after PCV7 vaccination compared with PPSV23 in moderate to severe COPD. We also posited that older age and prior PPSV23 vaccination would be associated with reduced vaccine responsiveness.
methodsOne hundred twenty patients with COPD were randomized to PPSV23 (63 subjects) or PCV7 (57 subjects). IgG concentrations were determined by ELISA; functional antibody activity was assayed with a standardized opsonophagocytosis assay and reported as an opsonization killing index (OPK). Increases in serotype-specific IgG and OPK at 1 month post vaccination were compared within and between vaccine groups. MEASUREMENTS AND MAIN
resultsBoth vaccines were well tolerated. Within each study group, postvaccination IgG and OPK were higher than baseline (P < 0.01) for all serotypes. Adjusted for baseline levels, postvaccination IgG was higher in the PCV7 group than the PPSV23 group for all seven serotypes, reaching statistical significance for five (P < 0.05). PCV7 resulted in a higher OPK for six of seven serotypes (statistically greater for four) compared with PPSV23. In multivariate analyses, younger age, vaccine naivety, and receipt of PCV7 were associated with increased OPK responses.
conclusionsPCV7 induces a superior immune response at 1 month post vaccination compared with PPSV23 in COPD. Older age and prior PPSV23 reduce vaccine responsiveness. Clinical trial registered with www.clinicaltrials.gov (NCT00457977).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.